Drug-induced interstitial lung disease (DIILD) is emerging as a hidden toll of modern oncology. Diagnosis of DIILD is confounded by non-specific symptoms and the absence of validated biomarkers, leaving clinicians to navigate heterogeneous, drug-specific guidelines. Herein, we discuss this predicament and advocate a shift from reactive management towards proactive survivorship.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Wang, D. Y. et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 4, 1721–1728 (2018).
Nishioka, N. et al. Real-world data on subsequent therapy for first-line osimertinib-induced pneumonitis: safety of EGFR-TKI rechallenge (Osi-risk study TORG-TG2101). Targ. Oncol. 19, 423–433 (2024).
Suresh, K. et al. Impact of checkpoint inhibitor pneumonitis on survival in NSCLC patients receiving immune checkpoint immunotherapy. J. Thorac. Oncol. 14, 494–502 (2019).
Li, B. T. et al. Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer. N. Engl. J. Med. 386, 241–251 (2022).
Modi, S. et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N. Engl. J. Med. 382, 610–621 (2020).
Tarantino, P., Ricciuti, B., Pradhan, S. M. & Tolaney, S. M. Optimizing the safety of antibody-drug conjugates for patients with solid tumours. Nat. Rev. Clin. Oncol. 20, 558–576 (2023).
Dolladille, C. et al. Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer. JAMA Oncol. 6, 865–871 (2020).
US Food & Drug Administration. TAGRISSO® (osimertinib) tablets, for oral use. Initial U.S. approval 2015. fda.gov https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s030lbl.pdf (2015).
Henning, J. W. et al. Managing the risk of lung toxicity with trastuzumab deruxtecan (T-DXd): a canadian perspective. Curr. Oncol. 30, 8019–8038 (2023).
Yamazaki, M. et al. 18F-FDG-PET/CT uptake by noncancerous lung as a predictor of interstitial lung disease induced by immune checkpoint inhibitors. Acad. Radiol. 32, 1026–1035 (2025).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Related links
NCCN Guidelines, non-small-cell lung cancer, version 7.2025: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1450
Supplementary information
Rights and permissions
About this article
Cite this article
Li, JX., Cheng, WC. Cured but breathless: the growing burden of DIILD in cancer survivors. Nat Rev Clin Oncol 22, 703–705 (2025). https://doi.org/10.1038/s41571-025-01064-4
Published:
Issue date:
DOI: https://doi.org/10.1038/s41571-025-01064-4
